Medical management after parathyroid intervention

Motoko Tanaka¹ and Masafumi Fukagawa²

¹Department of Nephrology, Akebono Clinic, Kumamoto, Kumamoto and ²Division of Nephrology and Kidney Center, Kobe University School of Medicine, Kobe, Hyogo, Japan

Abstract
Vitamin D or vitamin D analogues pulse therapy is seldom effective in patients with at least one parathyroid gland with nodular hyperplasia, and surgical parathyroidectomy or parathyroid intervention is indicated. In parathyroid interventions, especially in selective percutaneous ethanol injection therapy (PEIT), the enlarged parathyroid gland(s) with nodular hyperplasia is selectively destroyed by ethanol injection, while other glands with diffuse hyperplasia are managed by medical therapy. Thus, medical management, e.g., use of appropriate dose of vitamin D or vitamin D analogues after the PEIT procedure, is as important as the destruction of the hyperplastic tissue itself. Recent studies showed that the combination of PEIT and intravenous vitamin D pulse therapy lead to reduce serum PTH level and calcium-phosphorus products in haemodialysis patients. In this article, we focus on the importance of medical therapy after PEIT, and review the efficacy of the combination of PEIT and intravenous vitamin D pulse therapy for haemodialysis patients with secondary hyperparathyroidism.

Keywords: haemodialysis; intravenous vitamin D therapy; percutaneous ethanol injection therapy (PEIT); secondary hyperparathyroidism

Introduction
Secondary hyperparathyroidism with marked parathyroid hyperplasia is one of the most important complications in chronic dialysis patients [1]. Elevated serum phosphorus and calcium-phosphorus products and secondary hyperparathyroidism are associated with substantially high incidences of cardiac, visceral and peripheral vascular calcification in dialysis patients [2,3]. Cardiovascular disease accounts for nearly 50% of all deaths in dialysis patients, and the incidence of cardiovascular death in these patients is markedly higher than in the general population [4]. There is growing recognition that abnormal mineral metabolism and secondary hyperparathyroidism together play a key role in the morbidity and mortality in haemodialysis patients.

Percutaneous ethanol injection therapy (PEIT) is widely used in Japan as an alternative treatment for secondary hyperparathyroidism [5–8]. However, a few studies showed that PEIT was ineffective in severe secondary hyperparathyroidism in haemodialysis patients [9]. In this article, we focus on the importance of medical therapy after PEIT, and review the efficacy of the combination of PEIT and intravenous vitamin D pulse therapy for haemodialysis patients with secondary hyperparathyroidism.

Parathyroid size as a marker for refractory hyperparathyroidism
Parathyroid glands with the volume of 0.5 cm³ or diameter of 1 cm are considered critical for the diagnosis of nodular hyperplasia 10), 11). Vitamin D or vitamin D analogues pulse therapy is seldom effective in patients with even one gland diagnosed as nodular hyperplasia, and surgical parathyroidectomy or parathyroid intervention is indicated in such cases.

Recently, Vulpio et al. [12] reported that patients with moderate secondary hyperparathyroidism had a single enlarged parathyroid gland, whereas patients with severe secondary hyperparathyroidism exhibited more than one enlarged gland. They concluded that the ultrasonographic findings correlated with the severity of secondary hyperparathyroidism and therapeutic outcome. Thus, routine evaluation of the size and number of enlarged parathyroid glands assists in the selection of therapy for secondary hyperparathyroidism.

The theoretical basis of PEIT (Figure 1)
The theoretical basis of PEIT is that enlarged parathyroid gland(s) with nodular hyperplasia is destroyed ‘selectively’ by ethanol injection, while other glands with diffuse hyperplasia are managed by medical therapy, such as intravenous vitamin D analogues. Thus, medical management after the PEIT procedure is as important as the destruction of the hyperplastic tissue itself. In this respect, ‘selective PEIT’ is no longer an alternative to surgical parathyroidectomy, but rather has become a powerful adjunct to medical therapy.
As shown in Figure 1, the size of enlarged parathyroid gland was reduced after the PEIT procedure, which also improved resistance to medical therapy including vitamin D analogues.

**Difference between parathyroid intervention and parathyroidectomy**

Parathyroid intervention, i.e., surgical parathyroidectomy and direct injection therapy, should be reserved for refractory hyperparathyroidism associated with nodular hyperplasia. There are three surgical approaches: total parathyroidectomy with or without autotransplantation; subtotal parathyroidectomy and minimally invasive surgery [13,14]. In general, total parathyroidectomy with forearm autograft is preferred as a procedure for secondary hyperparathyroidism, especially in patients who would require long-term haemodialysis, because recurrently enlarged autograft can be easily removed from the forearm [13]. Direct injection therapy, such as PEIT, percutaneous calcitriol injection therapy (PCIT) and percutaneous maxacalcitol injection therapy (PMIT), is also an effective treatment for refractory hyperparathyroidism [15–17]. The main difference between parathyroidectomy and direct injection therapy is the selection of target glands. In total parathyroidectomy with autograft, all glands are surgically removed and fragments from the smallest gland are transplanted in the forearm, while in direct injection therapy, an enlarged gland with nodular hyperplasia is selectively destroyed by ethanol or other vitamin D compounds, while other glands with diffuse hyperplasia are managed by medical therapy. Thus, it is essential to use an appropriate dose of vitamin D analogue soon after direct injection therapy [8]. In a recent clinical study, patients with one hyperplastic gland responded well to PEIT as demonstrated by the efficacy rate, remission period and risk of relapse [18]. Thus, patients with one enlarged gland are the best indication for PEIT as recommended by the JSDT guidelines [19]. The selection of an optimal method for parathyroid intervention should be determined by the number and location of enlarged glands, as well as the presence of ectopic glands.

**Importance of medical therapy after PEIT procedure**

Several studies showed that PEIT is an effective treatment for refractory secondary hyperparathyroidism [5–8]. However, a few studies also demonstrated that PEIT was an ineffective treatment for severe secondary hyperparathyroidism in haemodialysis patients [9]. With respect to the number of enlarged glands and intensive medical therapy after PEIT, previous studies did not always select one enlarged gland and did not use an appropriate dose of vitamin D soon after PEIT. This might be a key point in securing appropriate outcome by PEIT for secondary hyperparathyroidism.

Based on the theoretical basis of PEIT, intensive medical therapy should be applied immediately after PEIT. We previously reported that the combination of intravenous maxacalcitol therapy and selective PEIT results in suppression of PTH secretion, regression of parathyroid hyperplasia and the control of calcium-phosphorus products and demonstrated the importance of medical therapy after PEIT [8].

Based on these evidences, we believe that the efficacy of PEIT depends on the number and location of enlarged glands, and the appropriate dose of vitamin D treatment after PEIT.

**Conclusions**

Disturbance in mineral and bone metabolism is one of the most important causes of increased cardiovascular mortality in chronic renal diseases. According to recent clinical guidelines, the control of parathyroid function in such patients should be achieved without the risk of vascular calcification. Parathyroid intervention should be reserved for patients with nodular hyperplasia to avoid prolonged and potentially even harmful medical therapy. Moreover, intensive medical therapy should be applied immediately after PEIT. Further studies are required to elucidate whether this combination therapy can improve the long-term prognosis of patients with secondary hyperparathyroidism.

**Conflict of interest statement.** None declared.

**References**

1. Fukagawa M, Kazama JJ, Shigematsu T. Management of patients with advanced secondary hyperparathyroidism: the Japanese approach. *Nephrol Dial Transplant* 2002; 17: 1553–1557
2. Block GA, Port FK. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. *Am J Kidney Dis* 2000; 35: 1226–1237
3. Ganesh SK, Stack AG, Levin NW et al. Association of elevated serum PO(4), Ca × PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. *J Am Soc Nephrol* 2001; 12: 2131–2138
4. Rostand SG, Druke TB. Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure. *Kidney Int* 1999; 56: 383–392
5. Fukagawa M, Kitaoka M, Tominaga Y et al. Japanese society for parathyroid intervention: guidelines for percutaneous ethanol injection therapy of the parathyroid glands in chronic dialysis patients. *Nephrol Dial Transplant* 2003; 18(Suppl 3): 31–33
6. Kitaoka M, Fukagawa M, Ogata E et al. Reduction of functioning parathyroid cell mass by ethanol injection in chronic dialysis patients. *Kidney Int* 1994; 46: 1110–1117
7. Kakuta T, Fukagawa M, Fujisaki T et al. Prognosis of parathyroid function after successful percutaneous ethanol injection therapy guided by color Doppler flow mapping in chronic dialysis patients. *Am J Kidney Dis* 1999; 33: 1091–1099
8. Tanaka M, Itoh K, Matsushita K et al. Combination therapy of intravenous maxacalcitol and percutaneous ethanol injection therapy lowers serum parathyroid hormone level and calcium × phosphorus product in secondary hyperparathyroidism. *Nephron Clin Pract* 2006; 102: c1–c7
9. de Barros Gueiros JE, Chammas MC, Gerhard R et al. Percutaneous ethanol (PEIT) and calcitrol (PCIT) injection therapy are ineffective in treating severe secondary hyperparathyroidism. *Nephrol Dial Transplant* 2004; 19: 657–663
10. Fukagawa M, Nakanishi S, Kazama JJ. Basic and clinical aspects of parathyroid hyperplasia in chronic kidney disease. *Kidney Int* 2006; 70: 53–57
11. Tominaga Y, Inaguma D, Matsuoka S et al. Is the volume of the parathyroid gland a predictor of Maxacalcitol response in advanced secondary hyperparathyroidism? *Ther Apher Dial* 2006; 10: 198–204
12. Vulpio C, Bossola M, De Gaetano A et al. Ultrasound patterns of parathyroid glands in chronic hemodialysis patients with secondary hyperparathyroidism. *Am J Nephrol* 2008; 28: 589–597
13. Tominaga Y, Uchida K, Haba T et al. More than 1,000 cases of total parathyroidectomy with forearm autograft for renal hyperparathyroidism. *Am J Kidney Dis* 2001; 38(Suppl 1): S166–S171
14. Kakuta T, Suzuki Y, Tadaki F et al. Long-term prognosis of parathyroid function for chronic dialysis patients after minimally invasive radio-guided parathyroidectomy (MIRP). *Nephrol Dial Transplant* 2003; 18(Suppl 3): 71–75
15. Nakamura M, Fuchinoue S, Teraoka S. Clinical experience with percutaneous ethanol injection therapy in hemodialysis patients with renal hyperparathyroidism. *Am J Kidney Dis* 2003; 42: 739–745
16. Kitaoka M, Onoda N, Kitamura H et al. Percutaneous calcitriol injection therapy (PCIT) for secondary hyperparathyroidism: multicentre trial. *Nephrol Dial Transplant* 2003; 18(Suppl 3): 38–41
17. Shiizaki K, Hatamura I, Negi S et al. Percutaneous maxacalcitol injection therapy regresses hyperplasia of parathyroid and induces apoptosis in uremia. *Kidney Int* 2003; 64: 992–1003
18. Koiwa F, Kakuta T, Tanaka R et al. Efficacy of percutaneous ethanol injection therapy (PEIT) is related to the number of parathyroid glands in haemodialysis patients with secondary hyperparathyroidism. *Nephrol Dial Transplant* 2007; 22: 522–528
19. Japanese society for dialysis therapy. Guidelines for the management of secondary hyperparathyroidism in chronic dialysis patients. *J Jpn Soc Dial Ther* 2006; 39: 1435–1455 (in Japanese)

Received for publication: 28.2.08
Accepted in revised form: 27.3.08